Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
about
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancerThe Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Novel investigational therapies for treating biliary tract carcinoma.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
P2860
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II study of saracatinib ...... metastatic colorectal cancer.
@ast
Phase II study of saracatinib ...... metastatic colorectal cancer.
@en
Phase II study of saracatinib
@nl
type
label
Phase II study of saracatinib ...... metastatic colorectal cancer.
@ast
Phase II study of saracatinib ...... metastatic colorectal cancer.
@en
Phase II study of saracatinib
@nl
prefLabel
Phase II study of saracatinib ...... metastatic colorectal cancer.
@ast
Phase II study of saracatinib ...... metastatic colorectal cancer.
@en
Phase II study of saracatinib
@nl
P2093
P2860
P50
P1476
Phase II study of saracatinib ...... d metastatic colorectal cancer
@en
P2093
C A Jimenez
D Fogelman
J L Abbruzzese
M J Overman
P2860
P2888
P304
P356
10.1007/S10637-015-0257-Z
P577
2015-06-12T00:00:00Z
P6179
1006453864